Crispr Liability.
1. Introduction
CRISPR liability refers to the legal responsibility of individuals, researchers, biotechnology companies, healthcare institutions, manufacturers, regulators and other entities for injury, damage, misuse or unlawful consequences arising from the development, application and commercialisation of CRISPR gene-editing technology.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), particularly CRISPR-Cas9, enables scientists to modify DNA by targeting particular genetic sequences. It has potential applications in treating genetic diseases, developing agricultural organisms, producing pharmaceuticals and conducting biomedical research.
However, CRISPR technology creates significant legal risks, including:
Unintended genetic mutations and off-target effects.
Inaccurate or incomplete gene editing.
Heritable genetic modifications affecting future generations.
Harm caused by experimental gene therapies.
Breaches of informed consent and research ethics.
Environmental damage from genetically modified organisms.
Misrepresentation of clinical safety and effectiveness.
Patent infringement and commercial exploitation.
Regulatory non-compliance and unlawful experimentation.
Discrimination and privacy violations involving genetic information.
CRISPR liability therefore involves several overlapping areas of law: tort law, medical negligence, product liability, criminal law, intellectual property, environmental law, constitutional principles and administrative regulation.
The central legal question is:
Who should be legally responsible when a CRISPR intervention causes harm, and what standard of care should apply to those developing, approving or administering the technology?
This discussion focuses primarily on Australian law, with important comparative international authorities.
2. Legal framework governing CRISPR liability in Australia
Australia does not have one comprehensive statute dealing exclusively with CRISPR liability. Instead, responsibility is determined through several legislative frameworks.
A. Gene Technology Act 2000 (Cth)
The Gene Technology Act 2000 establishes the national regulatory framework for dealings with genetically modified organisms (GMOs).
The legislation provides for:
Regulation of genetic modification activities.
Licensing of dealings involving GMOs.
Risk assessment and risk management.
Monitoring of authorised activities.
Regulatory supervision through the Office of the Gene Technology Regulator (OGTR).
Enforcement against unlawful dealings with GMOs.
CRISPR-modified organisms may fall within the regulatory framework depending on the nature of the modification and applicable statutory definitions and exemptions.
A researcher or institution undertaking regulated CRISPR activities without the required authorisation may face regulatory enforcement and applicable civil or criminal consequences.
The Australian regulatory scheme also operates through the Gene Technology Regulations 2001 and corresponding state and territory legislation.
Office of the Gene Technology Regulator
B. Therapeutic Goods Act 1989 (Cth)
Where CRISPR is used to develop human gene therapies, the Therapeutic Goods Act 1989 becomes particularly important.
The Therapeutic Goods Administration (TGA) regulates therapeutic goods, including relevant gene therapy products.
Legal responsibilities may arise where a company:
Supplies an unapproved therapeutic product unlawfully.
Makes misleading claims about treatment safety.
Fails to comply with applicable manufacturing standards.
Conducts clinical trials without the required regulatory arrangements.
Fails to report relevant safety information.
Distributes products that do not satisfy applicable legal requirements.
CRISPR-based medicines must satisfy applicable therapeutic-goods requirements. Scientific novelty does not exempt a product from regulatory scrutiny.
C. Australian Consumer Law
The Australian Consumer Law (ACL), contained in Schedule 2 of the Competition and Consumer Act 2010 (Cth), may apply to commercial CRISPR products and services.
Important protections include:
Section 18: misleading or deceptive conduct.
Section 29: false or misleading representations concerning goods or services.
Sections 54–59: consumer guarantees.
Sections 138–141: manufacturer liability for goods with safety defects.
For example, a biotechnology company advertising a CRISPR treatment as completely safe or guaranteed to eliminate a genetic disorder may incur liability if its representations are misleading.
A product may also give rise to statutory compensation claims where a safety defect causes injury or other legally recognised damage.
D. Work Health and Safety legislation
CRISPR research laboratories must comply with applicable work health and safety requirements.
Under the Work Health and Safety Act 2011 (Cth), where applicable, and corresponding state and territory legislation, persons conducting a business or undertaking have duties to protect workers and other persons from risks arising from their operations.
Potential liability includes:
Failure to provide laboratory safety procedures.
Inadequate training.
Improper handling of biological materials.
Failure to assess contamination risks.
Inadequate emergency arrangements.
Unsafe storage or disposal of genetically modified materials.
E. Privacy Act 1988 (Cth)
CRISPR research frequently involves genetic information, which can constitute sensitive personal information.
The Privacy Act 1988 regulates the collection, use, storage and disclosure of personal information by covered organisations.
Unauthorised disclosure of genetic information may create privacy liability, particularly where information identifies individuals or reveals inherited disease risks.
3. Major forms of CRISPR liability
A. Negligence liability
Negligence is one of the most important legal grounds for CRISPR-related claims.
A researcher, doctor, laboratory or biotechnology company may be liable where its failure to exercise reasonable care causes foreseeable injury.
The claimant generally needs to establish:
A duty of care.
Breach of that duty.
Factual and legal causation.
Recognised damage.
Example:
A biotechnology laboratory uses CRISPR-Cas9 to modify a patient's cells. The laboratory fails to conduct appropriate testing for unintended genetic mutations. The modified cells cause serious injury to the patient.
Depending on the evidence, the laboratory, treating institution and other responsible parties may face negligence claims.
Relevant failures may include inadequate validation, insufficient quality control, defective experimental protocols and failure to communicate known risks.
Important issue: CRISPR liability cannot automatically be established merely because an adverse outcome occurs. Courts must consider the applicable standard of care, scientific knowledge at the relevant time and the causal connection between the alleged breach and injury.
B. Medical negligence liability
Medical negligence arises where healthcare professionals administer CRISPR-based treatment without meeting the applicable professional standard.
Potential breaches include:
Administering experimental treatment without adequate justification.
Failure to explain alternative treatments.
Inadequate patient assessment.
Failure to disclose material risks.
Poor monitoring after treatment.
Failure to respond appropriately to complications.
In Australia, the applicable standard of care is informed by professional negligence legislation, including the Civil Liability Acts of the relevant jurisdictions.
C. Product liability
CRISPR products may include gene-editing kits, engineered cells, gene therapy products and genetically modified biological materials.
Manufacturers may face liability where defective products cause injury.
Examples include:
Contaminated CRISPR reagents.
Incorrectly manufactured gene-editing components.
Defective delivery systems.
Inadequate quality-control procedures.
Unintended genetic changes attributable to a defective therapeutic product.
Under the Australian Consumer Law, statutory manufacturer liability may arise under section 138 where a safety defect causes personal injury.
D. Research institution liability
Universities, hospitals and biotechnology research centres may face liability for failures in research governance.
Institutional responsibility may arise where there is:
Inadequate ethics review.
Failure to supervise researchers.
Failure to maintain laboratory safety.
Inadequate recordkeeping.
Failure to investigate adverse events.
Failure to ensure regulatory compliance.
An institution cannot necessarily avoid responsibility simply by arguing that the scientific experiment was conducted by an individual researcher.
Its liability will depend on the applicable statutory duties, employment relationships, institutional conduct and ordinary principles of negligence and vicarious liability.
E. Environmental liability
CRISPR can be used to modify plants, animals and microorganisms.
Environmental risks include:
Unintended spread of genetically modified organisms.
Genetic contamination of non-modified populations.
Changes to ecological relationships.
Unintended effects on biodiversity.
Persistence of modified organisms in the environment.
Under Australian environmental and gene technology legislation, relevant regulatory breaches may result in enforcement action.
Environmental claims may also arise under applicable statutory environmental duties and common-law principles where the necessary elements are established.
F. Criminal liability
Criminal liability may arise where CRISPR research involves deliberate unlawful conduct rather than an ordinary scientific mistake.
Examples include:
Unlawful medical practice.
Deliberate falsification of research documents.
Fraudulent clinical-trial reporting.
Knowingly unlawful dealings with regulated GMOs.
Intentional concealment of serious safety risks.
Criminally negligent conduct where the relevant offence is established.
The precise offence and mental element must be established under the applicable legislation. An unsuccessful experiment or unintended mutation does not automatically constitute a criminal offence.
4. Scientific risks that create legal liability
1. Off-target mutations
CRISPR may alter DNA at unintended locations. Failure to assess or disclose relevant risks can support negligence or product-liability claims.
2. Large genetic deletions
Editing may produce unexpected structural changes in DNA. Inadequate detection and quality assurance may create legal exposure.
“낳고 싶은 아이 선택, 알고리즘으로 아이 만든다”…실리콘밸리 ‘슈퍼 베이비’ 논란 - 매일경제
3. Germline editing
Changes to embryos or reproductive cells may be inherited by future generations, raising consent, human-subject protection and regulatory issues.
Zentrum für Gen- und RNA-Therapie | Universitätsklinikum Tübingen
4. Manufacturing defects
Incorrect preparation, contamination or inconsistent manufacturing may cause treatment-related injuries.
The legal significance of these risks depends on whether they were reasonably foreseeable, whether appropriate precautions were taken and whether they caused the alleged injury.
5. Important case laws relating to CRISPR liability
There are currently no leading reported Australian appellate judgments establishing a comprehensive doctrine of CRISPR-specific civil liability. However, several important judgments provide legal principles applicable to CRISPR research, medical treatment, genetic modification, informed consent and biotechnology patent disputes.
Case 1. Rogers v Whitaker (1992) 175 CLR 479
Australian High Court
Facts: A patient underwent eye surgery. The doctor failed to disclose a material risk associated with the proposed procedure, which subsequently resulted in serious injury.
Legal issue: Whether a medical practitioner has a duty to disclose material risks to a patient before treatment.
Judgment: The High Court recognised that doctors must disclose material risks. A risk is material where a reasonable person in the patient's position would likely attach significance to it, or where the doctor knows or ought to know that the particular patient would attach significance to it.
Application to CRISPR:
This judgment is particularly relevant to experimental gene-editing treatments.
A doctor proposing CRISPR-based treatment should appropriately explain:
Potential off-target mutations.
Uncertain long-term consequences.
Possible immune reactions.
Alternative treatments.
Possibility of treatment failure.
Known limitations of available scientific evidence.
A failure to disclose material risks may support a negligence claim.
Case 2. Wallace v Kam [2013] HCA 19
Australian High Court
Facts: A patient suffered nerve damage following spinal surgery. The doctor had failed to disclose relevant risks associated with the procedure.
Legal issue: Whether failure to warn about one risk could establish liability for an injury caused by a different risk.
Judgment: The High Court held that factual causation and the appropriate scope of liability must be examined separately. The doctor was not liable for the particular injury because the patient would have accepted the risk that actually materialised even if properly warned.
Application to CRISPR:
Suppose a patient receives CRISPR treatment after being informed about the possibility of immune reactions but not about a separate material risk of unintended genetic modification.
If unintended genetic modification causes injury, the court must examine whether the failure to warn caused the injury in the legally relevant sense.
The decision demonstrates that merely proving inadequate disclosure is insufficient: causation and the scope of liability must also be established.
High Court of Australia+1
Case 3. Confédération paysanne v Premier ministre (Case C-528/16, 2018)
European Court of Justice
Facts: Agricultural organisations challenged the treatment of organisms developed through newer genetic mutagenesis techniques under European GMO legislation.
Legal issue: Whether organisms produced using newer genetic modification techniques should be treated as genetically modified organisms under EU law.
Judgment: The Court held that organisms obtained through mutagenesis constitute GMOs under the relevant directive. Only organisms produced through mutagenesis techniques conventionally used in a number of applications with a long safety record fell within the relevant exemption.
Application to CRISPR:
The judgment is important because it demonstrates that newer genome-editing techniques cannot automatically escape GMO regulatory requirements merely because they do not necessarily introduce foreign DNA.
For CRISPR developers, the decision illustrates the importance of regulatory classification, risk assessment and environmental authorisation.
It is an EU regulatory judgment, not a direct statement of Australian law.
EUR-Lex+1
Case 4. University of California v Broad Institute, Inc. (2018)
US Federal Circuit
Citation: 903 F.3d 1286 (Fed. Cir. 2018).
Facts: The University of California and the Broad Institute disputed patent claims concerning CRISPR-Cas9 technology.
Legal issue: Whether the competing patent claims covered the same invention or patentably distinct applications of CRISPR-Cas9.
Judgment: The Federal Circuit affirmed the determination that there was no interference-in-fact between the relevant claims. It accepted that applying the technology to eukaryotic cells involved technical differences and that success was not reasonably predictable from the earlier work.
Application to CRISPR liability:
Although this was not a personal-injury case, it demonstrates that biotechnology companies and research institutions must carefully examine:
Patent ownership.
Inventorship.
Licensing rights.
Research agreements.
Commercial authorisation.
Potential infringement.
Unauthorised commercial use of patented CRISPR technology can create intellectual property liability independently of any physical injury.
Justia Law
Case 5. Regents of the University of California v Broad Institute, Inc. (2025)
Citation: US Court of Appeals for the Federal Circuit, Nos. 22-1594 and 22-1653, 12 May 2025.
Facts: The parties continued their dispute concerning priority of invention for CRISPR-Cas9 systems using single-guide RNA in eukaryotic cells.
Legal issue: Whether the patent tribunal applied the correct legal standard when evaluating conception and reasonable expectation of success.
Judgment: The Federal Circuit vacated part of the tribunal's priority determination and remanded the matter for reconsideration under the correct legal standard. It also affirmed the finding that the relevant earlier UC application lacked written-description support.
Application to CRISPR liability:
This decision is relevant to:
Scientific documentation.
Patent inventorship.
Experimental records.
Research collaboration agreements.
Commercial exploitation of genetic-editing inventions.
It illustrates that inadequate patent disclosure and disputed inventorship can create substantial legal exposure.
The subsequent patent proceedings also demonstrate that CRISPR intellectual property disputes remain ongoing.
Justia Law+1
Case 6. He Jiankui gene-edited babies criminal proceedings (China, 2019)
Criminal liability
Facts: Chinese scientist He Jiankui announced that he had used CRISPR-Cas9 to modify human embryos, resulting in the birth of gene-edited children.
The research involved editing the CCR5 gene with the stated objective of reducing susceptibility to HIV infection.
The experiment attracted international criticism because of its ethical, medical and scientific concerns.
Legal issue: Whether the conduct amounted to unlawful medical practice and violations of research regulations.
Judgment: In December 2019, a Chinese court convicted He Jiankui of illegally practising medicine and sentenced him to three years' imprisonment. Two collaborators also received criminal sentences.
The court proceedings involved findings concerning unlawful medical practice and falsification of ethical review materials.
Investing.com Canada+1
Application to CRISPR liability:
This case demonstrates that researchers may face criminal responsibility where they:
Conduct unauthorised human experimentation.
Falsify ethics approvals.
Misrepresent research procedures.
Undertake medical interventions without appropriate qualifications.
Violate mandatory research safeguards.
It also illustrates the importance of protecting future generations from potentially irreversible germline modifications.
Importantly, the case arose under Chinese law; it does not establish criminal liability under Australian legislation.
6. Liability for human germline editing in Australia
Human germline editing is one of the most legally sensitive applications of CRISPR technology.
Germline editing involves modifying reproductive cells or embryos in ways that may transmit genetic changes to future generations.
Australian law imposes particularly important restrictions in this area.
The principal legislation includes:
Prohibition of Human Cloning for Reproduction Act 2002 (Cth).
Research Involving Human Embryos Act 2002 (Cth).
Sections 15 and 20 of the Prohibition of Human Cloning for Reproduction Act prohibit specified practices involving alteration of the genome of a human cell in ways that may be inherited by descendants, subject to the statutory terms.
The National Health and Medical Research Council explains that some CRISPR research involving human embryos may be lawful under the applicable licensing framework, but using edited embryos for reproduction is prohibited under current legislation.
NHMRC+1
Legal consequences may include:
Criminal prosecution.
Imprisonment where the relevant offence is established.
Regulatory investigation.
Suspension or cancellation of research authorisations.
Institutional disciplinary action.
Professional consequences.
The distinction between permitted laboratory research and prohibited reproductive use is essential.
7. Who can be held liable for CRISPR-related harm?
| Responsible party | Potential legal responsibility |
|---|---|
| Scientist | Negligent research, unlawful experimentation or misconduct |
| Medical practitioner | Medical negligence and failure to disclose material risks |
| Biotechnology company | Product defects, misleading representations and regulatory breaches |
| Manufacturer | Defective reagents, delivery systems or therapeutic products |
| University | Institutional negligence and applicable vicarious liability |
| Hospital | Clinical negligence and inadequate patient monitoring |
| Ethics committee | Liability where an independent legal duty or other recognised basis is established |
| Research sponsor | Sponsor obligations, contractual liability and statutory breaches |
| GMO operator | Unauthorised dealings and environmental regulatory breaches |
| Commercial licensee | Patent infringement and breach of licensing obligations |
Important distinction: Not every participant is automatically liable. Courts determine responsibility by examining the particular duty, conduct, statutory obligation, causation and applicable defences.
8. CRISPR liability and informed consent
Informed consent is a fundamental requirement in human gene-editing research.
The consent process must be meaningful, voluntary and based on adequate information.
For CRISPR clinical trials, participants should receive information concerning:
The experimental nature of the treatment.
Potential unintended genetic alterations.
Known and uncertain medical risks.
Possible long-term consequences.
Data collection and genetic privacy.
Available alternative treatments.
Procedures for reporting adverse events.
Their right to withdraw from research, subject to applicable limitations.
Special issue: Consent of future generations
Germline editing creates a unique legal problem because future children cannot provide consent to genetic modifications made before their birth.
This raises questions about reproductive autonomy, intergenerational justice and the legal protection of future persons.
The inability to obtain consent from future generations strengthens the case for strict statutory restrictions and independent scientific oversight.
9. CRISPR liability under intellectual property law
CRISPR technology also generates disputes concerning ownership and commercial exploitation.
Potential legal claims include:
A. Patent infringement
Commercial use of patented CRISPR inventions without the necessary authorisation may constitute patent infringement.
B. Incorrect inventorship
False or incomplete identification of inventors may create patent disputes and contractual consequences.
C. Breach of licensing agreements
A biotechnology company may incur contractual liability by exceeding the scope of its CRISPR technology licence.
D. Misappropriation of confidential research
Unauthorised use of confidential laboratory information, research data or trade secrets may create civil liability.
The Broad Institute and University of California patent litigation demonstrates the importance of establishing inventorship, patent priority and the precise scope of patent claims.
10. Defences against CRISPR liability
A defendant facing a CRISPR-related claim may raise several legal defences, depending on the cause of action.
| Defence | Legal significance |
|---|---|
| No duty of care | The defendant may dispute the existence of a legally recognised duty. |
| No breach | The defendant may demonstrate compliance with the applicable standard of care. |
| Lack of causation | The defendant may dispute whether the alleged breach caused the injury. |
| Scientific uncertainty | Relevant to the assessment of reasonable care at the time, but not an automatic defence. |
| Informed consent | May be relevant to disclosure-related allegations, but does not excuse negligent treatment. |
| Contributory negligence | May reduce damages where applicable. |
| Statutory authorisation | May establish regulatory permission, but does not automatically eliminate civil liability. |
| Limitation period | A claim may be barred if brought outside the applicable statutory period. |
A particularly important distinction is that compliance with regulatory approval requirements does not necessarily establish that a CRISPR product is free from negligence or product liability.
11. Compensation and legal remedies
Where CRISPR-related harm is established, available remedies may include:
1. Compensatory damages: Compensation for personal injury, medical expenses, loss of earnings and other recognised losses.
2. Injunctions: Courts may restrain unlawful commercial activity or other conduct where the legal requirements for injunctive relief are satisfied.
3. Product liability remedies: Compensation for injuries caused by defective therapeutic products or other goods.
4. Regulatory penalties: Applicable penalties for breaches of gene technology, therapeutic goods or other regulatory legislation.
5. Criminal sanctions: Prosecution and punishment for offences involving unlawful medical practice, prohibited reproductive procedures, fraud or other relevant criminal conduct.
6. Patent remedies: Depending on the circumstances, patent owners may seek injunctions and damages or an account of profits for infringement.
12. Institutional accountability and prevention of CRISPR liability
Effective CRISPR governance requires a system of accountability extending beyond individual scientists.
CRISPR accountability framework
Scientific risk assessment
Off-target effects, unintended mutations and genetic stability
Ethics and regulatory approval
OGTR, TGA and Human Research Ethics Committees, as applicable
Laboratory and clinical quality control
Validation, manufacturing standards and monitoring
Adverse-event reporting
Investigation, documentation and corrective action
Legal accountability and compensation
Civil remedies, regulatory enforcement and criminal responsibility where applicable
Institutions should maintain:
Independent research ethics review.
Documented risk assessments.
Scientific validation records.
Clear responsibility for clinical decisions.
Long-term safety monitoring where justified.
Genetic information protection.
Adverse-event investigation mechanisms.
Appropriate insurance and indemnity arrangements.
13. Critical legal challenges in CRISPR liability
Several unresolved legal problems deserve particular attention.
A. Scientific uncertainty and the standard of care
CRISPR technology develops rapidly. Courts must determine reasonable professional conduct using the scientific knowledge available when the intervention occurred, rather than judging past conduct solely through subsequent discoveries.
B. Causation difficulties
A genetic mutation may arise from the editing procedure, the patient's underlying condition or another biological process. Establishing the causal relationship can require complex scientific evidence.
C. Long-term liability
Some genetic consequences may emerge many years after treatment. This creates difficulties concerning limitation periods, medical records, insurance and responsibility for long-term monitoring.
D. Multiple-party responsibility
CRISPR treatment may involve researchers, technology developers, manufacturers, sponsors and hospitals. Determining the respective responsibilities of these parties can be difficult.
E. Intergenerational liability
Germline editing raises the possibility of harm affecting individuals who were not parties to the original research or treatment.
F. Cross-border liability
A CRISPR intervention may be researched in one country, manufactured in another and administered in a third. Determining applicable law, jurisdiction and enforcement becomes particularly complicated.
14. Conclusion
CRISPR liability represents an emerging and complex area of biotechnology law. It combines traditional legal principles of negligence, product liability, informed consent, environmental protection, intellectual property and criminal responsibility with the distinctive risks of genetic engineering.
Australian law provides several important regulatory and civil liability mechanisms through the Gene Technology Act 2000, Therapeutic Goods Act 1989, Australian Consumer Law and human embryo legislation.
The judgments in Rogers v Whitaker, Wallace v Kam and Confédération paysanne provide important principles concerning disclosure, causation and the regulation of modern genetic modification. The He Jiankui proceedings further demonstrate the potential criminal consequences of unlawful human gene-editing experiments.
Ultimately, CRISPR liability should be based on scientific accountability, appropriate risk assessment, informed consent, regulatory compliance and effective remedies for persons harmed by unlawful or negligent interventions.
The central legal principle is that scientific innovation does not remove legal responsibility. Researchers and biotechnology companies must remain accountable for foreseeable risks, regulatory violations and harm caused by their activities.
15. Important legislation and case-law reference list
| Authority | Relevance |
|---|---|
| Gene Technology Act 2000 (Cth) | GMO regulation and licensing |
| Gene Technology Regulations 2001 | Regulatory implementation |
| Therapeutic Goods Act 1989 (Cth) | CRISPR therapeutic products |
| Competition and Consumer Act 2010 (Cth), Sch 2 | Consumer and product liability |
| Privacy Act 1988 (Cth) | Genetic information protection |
| Work Health and Safety Act 2011 (Cth) | Laboratory safety |
| Prohibition of Human Cloning for Reproduction Act 2002 (Cth) | Prohibited reproductive and germline practices |
| Research Involving Human Embryos Act 2002 (Cth) | Embryo research licensing |
| Rogers v Whitaker (1992) 175 CLR 479 | Medical disclosure and negligence |
| Wallace v Kam [2013] HCA 19 | Causation and scope of liability |
| Confédération paysanne C-528/16 | GMO classification and gene-editing regulation |
| University of California v Broad Institute (2018) | CRISPR patent disputes |
| Regents v Broad Institute (2025) | Patent priority and scientific disclosure |
| He Jiankui criminal proceedings (2019) | Unlawful human gene-editing research |
Useful primary legal resources:
Australian Federal Register of Legislation
Office of the Gene Technology Regulator
Therapeutic Goods Administration
Full judgment in Confédération paysanne v Premier ministre
Academic qualification: The Australian legal principles discussed above are established legal frameworks applied to CRISPR-related situations. They should not be mistaken for a settled body of Australian case law specifically concerning CRISPR injuries.
RELATED Blog
comments